SEGMENTED INFORMATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
SEGMENTED INFORMATION
Deferred tax	$ 12,305	$ 17,359
Income tax	(15,799)	(38,885)
Total tax (expense)/credit	(3,494)	(21,526)
Net Income (Loss) Available to Common Stockholders, Basic	(1,598,342)	(2,629,043)
REVENUE	9,510,646	9,770,806
COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)	(8,221,125)	(8,441,308)
GROSS PROFIT	1,289,521	1,329,498
OTHER INCOME	2,072,473	486,036
Sales and marketing	(2,030,684)	(596,858)
Research and development	(47,511)	(54,982)
General and administrative	(1,973,968)	(2,442,855)
Provision for expected credit losses	(883,533)	(1,314,427)
TOTAL OPERATING EXPENSES	(4,935,696)	(4,409,122)
LOSS FROM OPERATIONS	(1,573,702)	(2,593,588)
FINANCE COSTS	(21,146)	(13,929)
LOSS BEFORE TAX	(1,594,848)	(2,607,517)
Provision For Genomic Screening Services [Member]
SEGMENTED INFORMATION
Deferred tax	0	12,269
Income tax	0	(2,613)
Total tax (expense)/credit	0	9,656
Net Income (Loss) Available to Common Stockholders, Basic	(246,939)	(217,146)
REVENUE	16,069	24,219
COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)	(7,316)	(19,851)
GROSS PROFIT	8,753	4,368
OTHER INCOME	122,951	19,629
Sales and marketing	(125,299)	(18,884)
Research and development	(47,511)	(54,982)
General and administrative	(194,038)	(171,881)
Provision for expected credit losses	0	0
TOTAL OPERATING EXPENSES	(366,848)	(245,747)
LOSS FROM OPERATIONS	(235,144)	(221,750)
FINANCE COSTS	(11,795)	(5,052)
LOSS BEFORE TAX	(246,939)	(226,802)
Investment Holding [Member]
SEGMENTED INFORMATION
Deferred tax	0	0
Income tax	0	0
Total tax (expense)/credit	0	0
Net Income (Loss) Available to Common Stockholders, Basic	(1,144,817)	(2,144,374)
REVENUE	0	0
COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)	0	0
GROSS PROFIT	0	0
OTHER INCOME	0	0
Sales and marketing	(43,929)	(8,078)
Research and development	0	0
General and administrative	(1,100,609)	(2,136,296)
Provision for expected credit losses	0	0
TOTAL OPERATING EXPENSES	(1,144,538)	(2,144,374)
LOSS FROM OPERATIONS	(1,144,538)	(2,144,374)
FINANCE COSTS	(279)	0
LOSS BEFORE TAX	(1,144,817)	(2,144,374)
Trading Of Industrial Chemicals [Member]
SEGMENTED INFORMATION
Deferred tax	12,305	5,090
Income tax	(15,799)	(36,272)
Total tax (expense)/credit	(3,494)	(31,182)
Net Income (Loss) Available to Common Stockholders, Basic	(206,586)	(267,523)
REVENUE	9,494,577	9,746,587
COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)	(8,213,809)	(8,421,457)
GROSS PROFIT	1,280,768	1,325,130
OTHER INCOME	1,949,522	466,407
Sales and marketing	(1,861,456)	(569,896)
Research and development	0	0
General and administrative	(679,321)	(134,678)
Provision for expected credit losses	(883,533)	(1,314,427)
TOTAL OPERATING EXPENSES	(3,424,310)	(2,019,001)
LOSS FROM OPERATIONS	(194,020)	(227,464)
FINANCE COSTS	(9,072)	(8,877)
LOSS BEFORE TAX	$ (203,092)	$ (236,341)